Healthcare Professionals | Full Prescribing Information | Glossary | Register | Unsubscribe
LUMIGAN® Logo Glossary LUIGAN® Header
Test
      Your Eyesight
      About LUMIGAN®
      Tools and Resources
  Full Prescribing Information
Glossary
LUMIGAN® Header

asymptomatic: to have no symptoms of disease; evidence of disease is not noticeable by the patient

chronic: a disease having a long duration, typically a lifelong condition that can be treated but not cured

cornea: the transparent, bowl-shaped structure at the front of the eye covering the iris and the pupil

cupping: the indentation in the optic disc; cupping can increase (deepen) over time as a result of progression of glaucoma disease
diminishes: reduces; lessens

disease progression: the worsening of a disease characterized by increased tissue or organ damage and/or worsening of symptoms (eg, deterioration of vision)

elevated IOP: raised or increased intraocular pressure; high eye pressure

glaucoma: a group of eye diseases (many different types) resulting in damage to the optic nerve; commonly characterized by elevated IOP; can lead to blindness if left untreated

glaucomatous: related to or affected by glaucoma

gradual: changing little by little over time

hyperemia: conjunctival hyperemia is the medical term for increased eye redness

IOP: intraocular pressure; the pressure within the eyes

irreversible: not able to be corrected; permanent

LUMIGAN®: LUMIGAN® is an eye drop medication used to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

mmHg: millimeters of mercury; how IOP is measured

normal-pressure glaucoma: a type of open-angle glaucoma in which IOP is within normal range, yet the optic nerve is still damaged and there is a visual field defect; also called low-tension or normal-tension glaucoma

ocular hypertension: consistent elevated eye pressure (IOP); high IOP but without any detectable visual field defect or optic nerve damage

open-angle glaucoma: the most common form of glaucoma; typically characterized by chronic elevated IOP, optic nerve damage, and visual field loss

ophthalmoscope: a medical device used to view the interior of the eye (including the optic nerve head)

optic disc: area in the back of the eye where the optic nerve leaves the eye

optic nerve: the nerve that carries visual images from the eye, specifically the retina, to the brain

perimetry test: a test that measures an individual’s visual field (range of vision); also called visual field test

peripheral vision: area of view that is not the center focus; eg, side vision or what you may see “out of the corner of your eye”

primary: the first or of the highest rank of importance

retina: the innermost layer of the eye; sends visual images as electrical messages through the optic nerve to the brain

RGC: retinal ganglion cells are found in the retina, convert images received into electrical messages, and then send those messages to the optic nerve

risk factor: a medical, hereditary, or behavioral characteristic associated with increased likelihood of developing a disease

tonometry: a type of test used to measure IOP (eye pressure)

visual field: the entire field of vision, central and peripheral; measured by a perimetry test

visual field defect: a missing area or spot in the visual field; in patients with glaucoma, the first sign of visual field defect typically occurs in the peripheral or side vision

visual field loss: in patients with glaucoma, it is the deterioration of vision over time; typically, the side or peripheral vision is lost first, characterized by a narrowing of what is seen outside of center focus


Print this page
Support Network
Customized tools
to help you succeed with treatment.
   
 
Sign up
 
 
 

LUMIGAN (bimatoprost ophthalmic solution) 0.03% is for the treatment of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.

Important Safety Information
LUMIGAN (bimatoprost ophthalmic solution) 0.03% has been reported to cause darkening (pigmentation) of eye color, eyelid skin and eyelashes, as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN is used. After stopping LUMIGAN®, darkening of eye color is likely to be permanent while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond 5 years are not known.

The most common side effects are eye redness, growth of eyelashes, and itchy eyes.

LUMIGAN® Footer
  Privacy Policy Terms of Use
ALLERGAN
LUMIGAN® Footer